Binocular Treatment of Amblyopia
General Overview
- Amblyopia: Developmental visual disorder from abnormal binocular experience in early childhood, leading to visual cortex suppression of the weaker eye.
- Causes: Anisometropia (unequal image clarity/contrast), strabismus (misalignment), deprivation (e.g., ptosis, cataract).
- Prevalence: 99.2 million (2019), projected 175.2 million (2030).
- Neuroplasticity: Key to recovery; highest in childhood but residual in adults, offering treatment potential beyond early years.

Traditional Treatment
- Gold standard: Refractive correction + penalization (patching or pharmacologic therapy) to promote amblyopic eye use.
- Penalization: Monocular approach; reduces fellow eye input.
- Patching dose: Minimum 14 hours/week (PEDIG recommendation).

Binocular/Dichoptic Therapy
- Definition: Forces simultaneous use of both eyes to restore binocular fusion and stereopsis via dichoptic stimulation.
- Paradigms:
  1. Low contrast/brightness in fellow eye or stimuli only to amblyopic eye.
  2. Complementary dichoptic deficits (e.g., blurred fellow eye fovea, split images) to engage both eyes.
- Weekly dose: 4–7.5 hours (less than patching).
- Noninferior to patching: Systematic review (20 RCTs, n=1769) shows equivalent or better efficacy vs. patching.
- Adherence: Higher than patching (often 76–100%, PEDIG “excellent” classification).

Key Outcomes
- Amblyopic eye best-corrected visual acuity (AEBCVA): Primary outcome measure; significant improvements with binocular therapy.
- Stereopsis: Often improves alongside VA.
- Binocular function: Enhanced by design, unlike monocular penalization.

Specific Therapies and Evidence
- Luminopia One (VR goggles, FDA-cleared): 1.8 logMAR lines (12 weeks) vs. 0.8 lines (glasses alone); meta-analysis shows 1.6 lines.
- CureSight (anaglyph glasses + eye tracker, FDA-cleared): 2.8 lines (16 weeks), noninferior/superior to patching (2.3 lines); long-term: 2.7 lines (12 weeks post), 2.0 lines (1 year post).
- Contrast-rebalanced dichoptic movies: 0.7–1.8 lines (2–6 weeks), similar to patching.
- Dig Rush game: Variable results (superior in some trials, minimal in others), possibly due to adherence.
- Falling Blocks game: Promising in nonrandomized studies, but RCTs show no superiority over patching/placebo.
- Vivid Vision (VR): 0.89 lines (10 weeks) vs. 1.38 lines (patching); sustained gains post-therapy (1.32 lines).
- Dichoptic Tetris: 2.1 lines (3 months), equal to patching (2.2 lines); superior contrast sensitivity.
- Bynocs: 1.5–3.0 lines (6 weeks); improves binocular function score (BFS).


Med Device Monday - Luminopia One, A Digital Therapeutic to Help Treat Amblyopia
Luminopia FDA-Approved Medical Device Treatment for Amblyopia




Recent Studies (Past 18 Months)
- CureSight RCT: 2.8 lines (superior to patching by 0.5 lines with ≥60% adherence).
- Nintendo dichoptic cartoons: 1.1 lines (2 weeks), superior to patching; 1.6 lines (4 weeks).
- Balanced binocular viewing (Nintendo): 1.8 lines (16 weeks), equal to patching (2.0 lines).
- VR in-office: Median 3.0 lines (24 weeks), equal to patching (2.0 lines).
- Immersive 3D movie: 0.6 lines + 40% stereopsis improvement (3 months).
- NEIVATECH VR: 1.2 lines (1 month) + BFS improvement.

Adults and Teenagers
- Binocular therapy effective in older patients (unlike traditional treatments, where efficacy declines with age).
- Examples:
  - Bynocs: 2.9 lines (adults) vs. 3.1 lines (children).
  - Vivid Vision: Significant gains in adults/teenagers, not with patching.
  - Dichoptic Tetris: Significant gains in teens (13–15 years).

Recurrence Rates
- CureSight: 5.3% (12 weeks post), 20.4% (1 year post).
- General binocular therapy: 28% (3 years post).
- Patching/atropine: 24% (1 year post) for comparison.

Complementary Treatment
- Patching + 3D video: 1.7 lines (6 weeks), superior to patching alone (0.5 lines) + BFS improvement.
- Patching + VisionarySuite: 3.1 lines (6 months) vs. 1.8 lines (patching alone), no significant difference.


Clinical Implications
- Consider as first-line or adjunct therapy: Especially for older patients or those resistant/noncompliant with patching.
- Advantages: Home accessibility, high adherence, lower dosage.
- Research gaps: Superiority claims, long-term stability, specific guidelines by age/etiology.